PH26234A - Agent for treating bradycardia and bradyaarythmia - Google Patents
Agent for treating bradycardia and bradyaarythmia Download PDFInfo
- Publication number
- PH26234A PH26234A PH38045A PH38045A PH26234A PH 26234 A PH26234 A PH 26234A PH 38045 A PH38045 A PH 38045A PH 38045 A PH38045 A PH 38045A PH 26234 A PH26234 A PH 26234A
- Authority
- PH
- Philippines
- Prior art keywords
- oxobutyl
- piperidinecarboxamide
- thyl
- compounds
- animal
- Prior art date
Links
- 208000006218 bradycardia Diseases 0.000 title claims description 9
- 230000036471 bradycardia Effects 0.000 title claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 150000007522 mineralic acids Chemical class 0.000 claims description 4
- 150000007524 organic acids Chemical class 0.000 claims description 4
- 235000005985 organic acids Nutrition 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 206010049765 Bradyarrhythmia Diseases 0.000 claims description 3
- 150000003278 haem Chemical class 0.000 claims 2
- JSPCTNUQYWIIOT-UHFFFAOYSA-N piperidine-1-carboxamide Chemical compound NC(=O)N1CCCCC1 JSPCTNUQYWIIOT-UHFFFAOYSA-N 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 239000000126 substance Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 239000013543 active substance Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 230000027455 binding Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 4
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 4
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 4
- 229960004373 acetylcholine Drugs 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 230000001022 anti-muscarinic effect Effects 0.000 description 3
- 210000003710 cerebral cortex Anatomy 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 241000700198 Cavia Species 0.000 description 2
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920000715 Mucilage Polymers 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001078 anti-cholinergic effect Effects 0.000 description 2
- 150000003857 carboxamides Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 239000002287 radioligand Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
- 229960001462 sodium cyclamate Drugs 0.000 description 2
- 230000001515 vagal effect Effects 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical class OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 240000004760 Pimpinella anisum Species 0.000 description 1
- 235000012550 Pimpinella anisum Nutrition 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical group O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
- LZCOQTDXKCNBEE-IKIFYQGPSA-N methscopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)C)=CC=CC=C1 LZCOQTDXKCNBEE-IKIFYQGPSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960001383 methylscopolamine Drugs 0.000 description 1
- 239000003149 muscarinic antagonist Substances 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000001913 submandibular gland Anatomy 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000000213 tachycardiac effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3800868A DE3800868A1 (de) | 1988-01-14 | 1988-01-14 | Mittel zur behandlung von bradycardien und bradyarrhythmien |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH26234A true PH26234A (en) | 1992-04-01 |
Family
ID=6345259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH38045A PH26234A (en) | 1988-01-14 | 1989-01-13 | Agent for treating bradycardia and bradyaarythmia |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US4904673A (ja) |
| EP (1) | EP0324348A3 (ja) |
| JP (1) | JPH01216929A (ja) |
| KR (1) | KR890011595A (ja) |
| AU (1) | AU610331B2 (ja) |
| DE (1) | DE3800868A1 (ja) |
| DK (1) | DK730788A (ja) |
| HU (1) | HU201243B (ja) |
| PH (1) | PH26234A (ja) |
| ZA (1) | ZA89282B (ja) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3919075A1 (de) * | 1989-06-10 | 1990-12-13 | Thomae Gmbh Dr K | Mittel zur behandlung von erkrankungen des zentralnervensystems und zur foerderung der cerebralen durchblutung |
| US5437291A (en) * | 1993-08-26 | 1995-08-01 | Univ Johns Hopkins | Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA705408A (en) * | 1965-03-09 | A. J. Janssen Paul | 1-(.omega.,.omega.-DIPHENYLALKYL)-4-AMINO-4-PIPERIDINE-CARBOXAMIDES AND DERIVATIVES THEREOF | |
| NL130088C (ja) * | 1960-03-14 | |||
| GB932487A (en) * | 1960-07-25 | 1963-07-31 | D G Searle & Co | Piperidine derivatives |
| GB949729A (en) * | 1960-11-15 | 1964-02-19 | Bofors Ab | Substituted-piperidine carboxylic acid amide salts and their preparation |
| US4547514A (en) * | 1983-12-05 | 1985-10-15 | A. H. Robins Company, Incorporated | Aryloxy-N-(aminoalkyl)-1-pyrrolidine and piperidine carboxamides and carbothioamides having antiarrhythmic activity |
| IL74140A (en) * | 1984-04-10 | 1988-05-31 | Robins Co Inc A H | Substituted n-((amino)alkyl)-1-pyrrolidine,-1-piperidine and-1-homopiperidine-carboxamides and pharmaceutical compositions containing them |
| US4560692A (en) * | 1984-07-18 | 1985-12-24 | Hoffmann-La Roche Inc. | 4-Piperidino-2-phenylquinolines |
| EP0177078A1 (en) * | 1984-09-12 | 1986-04-09 | Duphar International Research B.V | Spasmolytically active tertiary amine derivatives and method of preparing the same |
-
1988
- 1988-01-14 DE DE3800868A patent/DE3800868A1/de not_active Withdrawn
- 1988-12-30 DK DK730788A patent/DK730788A/da not_active Application Discontinuation
-
1989
- 1989-01-03 EP EP19890100033 patent/EP0324348A3/de not_active Withdrawn
- 1989-01-13 JP JP1007575A patent/JPH01216929A/ja active Pending
- 1989-01-13 PH PH38045A patent/PH26234A/en unknown
- 1989-01-13 AU AU28462/89A patent/AU610331B2/en not_active Ceased
- 1989-01-13 ZA ZA89282A patent/ZA89282B/xx unknown
- 1989-01-13 HU HU89126A patent/HU201243B/hu unknown
- 1989-01-13 KR KR1019890000292A patent/KR890011595A/ko not_active Application Discontinuation
- 1989-01-17 US US07/298,078 patent/US4904673A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU610331B2 (en) | 1991-05-16 |
| DK730788D0 (da) | 1988-12-30 |
| US4904673A (en) | 1990-02-27 |
| HU201243B (en) | 1990-10-28 |
| JPH01216929A (ja) | 1989-08-30 |
| DK730788A (da) | 1989-07-15 |
| HUT50041A (en) | 1989-12-28 |
| KR890011595A (ko) | 1989-08-21 |
| EP0324348A3 (de) | 1990-10-24 |
| AU2846289A (en) | 1989-07-20 |
| DE3800868A1 (de) | 1989-07-27 |
| ZA89282B (en) | 1990-09-26 |
| EP0324348A2 (de) | 1989-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1272218B1 (en) | A pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines | |
| JP2023533447A (ja) | がんを処置する併用療法 | |
| JP2003514013A (ja) | 医薬組成物 | |
| TW200843734A (en) | Use of arsenic compounds for treatment of pain and inflammation | |
| SK4862000A3 (en) | The use of 5-ht3 receptor antagonists | |
| KR19990067527A (ko) | 동통의 치료를 위한 에피나스틴의 용도 | |
| AU2002348224A1 (en) | Endothelin antagonists ina method and composition for potentiating an opiate analgesic | |
| JPH08183735A (ja) | 不安症の治療 | |
| JPH11501282A (ja) | コリン受容体作用薬及び拮抗薬としてのエピバチジン及びその誘導体 | |
| JP2005501023A (ja) | Ｐｄｅ−４阻害剤およびｈ１受容体アンタゴニストを含んでなる組成物、および呼吸器疾患の治療のための医薬の製造におけるその使用 | |
| KR20040027892A (ko) | 편두통의 치료를 위한 기타 항편두통 약물과의 배합물에서βⅰβν4096의 용도 | |
| US20120329779A1 (en) | Method of Treating Mixed Lineage Leukemia Gene-Rearranged Acute Lymphoblastic Leukemias | |
| US5990125A (en) | NK-1 receptor antagonists for the treatment of cancer | |
| US5767130A (en) | Use of kainic acid antagonists to prevent toxic side effects of NMDA antagonists | |
| KR101318806B1 (ko) | 메틸페니데이트 유도체 및 그 용도 | |
| PH26234A (en) | Agent for treating bradycardia and bradyaarythmia | |
| KR100195651B1 (ko) | 신경 손상 및 발작의 치료를 위한 nk-1 수용체 길항물질 | |
| EP0773026A2 (en) | NK-1 receptor antagonists for the treatment of cancer | |
| KR20220113411A (ko) | KV7 칼륨 채널 개방제(opener)의 통증 치료를 위한 용도 | |
| JPH10167969A (ja) | 姑息的腫瘍療法でのドーパミンレセプター−アンタゴニストの使用 | |
| JP2001139490A (ja) | うつ病及び不安に対する組合せ治療 | |
| JP2003530341A (ja) | 不安の治療におけるサブコメリンの使用 | |
| CZ119197A3 (en) | Benzothiophene for preparing a medicament | |
| US20040001895A1 (en) | Combination treatment for depression and anxiety | |
| WO2023165479A1 (zh) | 硝酮化合物或其在药学上可接受的盐与sglt-2抑制剂联合应用 |